FibroBiologics (FibroBiologics) Change In Payables And Accrued Expense : $1.84 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Change In Payables And Accrued Expense?

FibroBiologics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $1.23 Mil. It means FibroBiologics's Accounts Payable & Accrued Expense increased by $1.23 Mil from Dec. 2023 to Mar. 2024 .

FibroBiologics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.81 Mil. It means FibroBiologics's Accounts Payable & Accrued Expense increased by $0.81 Mil from Dec. 2022 to Dec. 2023 .

FibroBiologics Change In Payables And Accrued Expense Historical Data

The historical data trend for FibroBiologics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Change In Payables And Accrued Expense Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

0.23

0.53

0.81

FibroBiologics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial				0.20	-0.02	0.36	0.28	1.23

FibroBiologics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.84 Mil.

FibroBiologics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (FibroBiologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

SG0:Germany

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines

From GuruFocus

FibroBiologics Announces Three United States Patents for Fibroblast Technology

By PRNewswire • 02-12-2024

FibroBiologics Announces Three Japanese Patents on Fibroblast Technology

By PRNewswire • 02-12-2024